



**Item 8.01 Other Events**

BioCryst Pharmaceuticals, Inc. (the Company) announced the initiation of a Phase II study of intramuscular (i.m.) peramivir for the treatment of seasonal influenza.

On July 10, 2008, the Company issued a press release entitled BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza a copy of which is filed herewith as Exhibit 99.1.

Neither the filing of any press release as an exhibit to this Current Report on Form 8-K nor the inclusion in such press release of a reference to Registrant's Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K. The information available at Registrant's Internet address is not part of this Current Report on Form 8-K or any other report filed by Registrant with the Securities and Exchange Commission.

**Item 9.01. Financial Statements and Exhibits:**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated July 10, 2008 entitled BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 10, 2008

**BioCryst Pharmaceuticals, Inc.**

By: /s/ Michael A. Darwin

Michael A. Darwin  
Principal Accounting Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated July 10, 2008 entitled BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza